Month: May 2021

Press release May 14, 2021, 15:30 Sdiptech divests Aufzüge Friedl GmbH and ST Lift GmbH Sdiptech AB (publ) has today entered into an agreement to divest its elevator business in Austria consisting of Aufzüge Friedl GmbH and ST Lift GmbH (together Aufzüge Friedl) to founder and minority owner Jürgen Friedl. The purchase price for Sdiptech’s holding of 51 percent amounts to EUR 6 million on a cash and debt-free basis. Sdiptech’s Austrian elevator operations Aufzüge Friedl specialises in the renovation, modernisation and service of elevators in Vienna. The business units are part of Sdiptech’s business area Property Technical Services and currently have annual sales of approximately EUR 8 million and an operating profit (EBIT) of approximately EUR 1 million, of which Sdiptech’s share is 51 percent. The sale is conducted...

TORONTO, May 14, 2021 (GLOBE NEWSWIRE) — Guardian Capital Group Limited (“Guardian”) announced the results of the director elections at its annual meeting of shareholders held on Thursday, May 13, 2021. Each of the following nominees was elected as a director of Guardian to serve until the termination of the next annual meeting of shareholders:       Name of NomineeVotes FOR (%) Votes WITHHELD (%)James S. Anas 94.85 5.15A. Michael Christodoulou 99.76 0.24Petros Christodoulou 99.99 0.01Marilyn De Mara 99.99 0.01Harold W. Hillier 99.99 0.01George Mavroudis 94.85 5.15Edward T. McDermott 99.99 0.01Barry J. Myers 99.99 0.01Hans-Georg Rudloff 94.85 5.15In addition to the election of directors, shareholders also appointed KPMG LLP, Chartered Professional Accountants, Toronto, Ontario, as auditors of...

In April, “Novaturas” Group resumed flights from Lithuania, Latvia, and Estonia to the most popular summer destination – Turkey. During April, the Company served 10.2 thousand customers. In total, during January – April, the Company served 19 thousand customers – 31% less than last year and 71% less than in 2019. Group revenue in April amounted to EUR 6.4 million.  Cumulative January – April turnover reached EUR 12 million and was 49% and 72% lower than the corresponding time last year and in 2019.  “While presenting the successful results of the first quarter to the investor community, we have forecasted that in the upcoming each month of the second quarter our target is to serve more than 10 thousand travelers on a group-wide basis. We have achieved this result in April, and it is highly likely to generate similar...

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, today announces financial results for the fiscal quarter ended March 31, 2021, and provides an update on recent company developments. Key developments from Q1 2021 and to date include:Atossa concluded its open-label Phase 2 clinical study of oral Endoxifen administered in the “window of opportunity” between diagnosis of breast cancer and surgery based on positive results allowing acceleration of the Endoxifen program in the United StatesAnnounced updated findings following 24 months of an Expanded Access (or “compassionate use”) single-patient study of Endoxifen...

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) — Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the closing of its previously announced underwritten public offering of 15,333,332 shares of its common stock, including 1,999,999 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares to cover over-allotments, at a public offering price of $2.25 per share. The gross proceeds to Recro from this offering are approximately $34.5 million, before underwriting discounts and commissions and estimated offering expenses.   Recro intends...

The Annual General Meeting of Shareholders of AB „Rokiškio sūris“ (company code 173057512, address Pramonės str.3, Rokiškis), which took place on 30 April 2021, decided to allocate EUR 0.10 per share for 2020 (the total amount of dividends for 2020 is EUR 3.501 million). Dividends will be paid to those persons who at the end of the tenth business day following the General Meeting of Shareholders accepting the payment of dividends, i.e. May 14, 2021 will be shareholders of AB Rokiškio sūris. As of May 26, 2021, dividends will be paid in the following order:For shareholders whose bookkeeping of AB Rokiškio sūris shares is managed by financial brokerage firms or branches of credit institutions providing securities accounting services, the amount of dividends after deduction of personal income tax or income tax under the laws of the Republic...

SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021. CEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021. Investors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference. Investors can register for the conference here. About Atossa Therapeutics Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant...

CALGARY, Alberta, May 14, 2021 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (“Divergent”, the “Company”, or “DVG”) is pleased to announce the appointment of Ken Olson as Interim Chief Financial Officer of the Company, effective May 17, 2021, replacing Lance Mierendorf who has chosen to leave the Company to pursue another opportunity, effective May 15, 2021. Mr. Olson has over 28 years of finance and accounting experience, including 12 years in executive leadership positions within the oilfield services sector. In these roles he provided executive leadership with equity financing, acquisitions & divestitures, corporate restructurings, corporate governance, and building global finance teams. Prior thereto, Ken spent 6 years with a technology company in numerous positions and 12 years with PricewaterhouseCoopers. Ken Berg,...

FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the company will participate and be available for 1×1 meetings at the following upcoming conference:Oppenheimer Rare & Orphan Disease SummitDate: May 21, 2021Time: On demand presentation for registered participants  Available for 1×1 meetingsWebcast: To register, click on the link HEREA replay of the presentation will be available on the Events page of the company website. About Cellectar Biosciences, Inc.Cellectar Biosciences is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently...

LAKEWOOD, N.J., May 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW), which combines AI and cloud-based technologies with the personalized experience of a traditional insurance agency, today provided a business update and reported financial results for the first quarter ended March 31, 2021. Ezra Beyman, CEO of Reliance Global Group, commented, “We continue to execute on our organic growth strategy as evidenced by a 15% increase in revenue for the first quarter of 2021 over the same period last year.  I am also pleased to report that we continue to increase the cash flow from our insurance operations.   We ended the quarter with over $10 million of cash and restricted cash, which provides us a solid balance sheet to execute on our near and long-term growth objectives.  At the...